The trials for this new TB vaccine have been taking place in sub-Saharan Africa for several years and the long-term Phase 2b results have finally been published.

Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal Vaccine.

A clinical trial published in the New England Journal ... reduced the risk of developing drug-resistant tuberculosis (TB), and almost halved adults' and children's risk of developing multidrug ...

Krishna Ella, Executive Chairman Bharat Biotech said Our quest for a more effective vaccine against Tuberculosis received a big boost today, with clinical trials in India. Our goal to develop TB ...